Investors & Media

Press Releases

Press Releases

Date Title View
Toggle Summary Sage Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 10, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast
View HTML
Toggle Summary Sage Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 4, 2022-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will present
View HTML
Toggle Summary Sage Therapeutics’ Third Annual FutureCast Showcases Data from All Three Brain Health Franchises
In the open-label LUMINARY Study, SAGE-718 improved performance from baseline on multiple tests of cognitive function in patients with Alzheimer’s disease mild cognitive impairment and mild dementia, consistent with positive signals seen in Parkinson’s disease and Huntington’s disease Now enrolling
View HTML
Toggle Summary Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology (ACNP) Congress
Patients receiving zuranolone 50 mg in the WATERFALL Study demonstrated rapid improvements in depressive and anxiety symptoms, as early as the first measured timepoint (Day 3 for HAMD-17 and Day 8 for HAM-A), with average improvements maintained through the end of the study (Day 42) Safety data
View HTML
Toggle Summary Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD
In the zuranolone 50 mg cohort, the majority of patients who responded to an initial 14-day course received only one two-week course of treatment during the study and nearly 80% received only one or two treatment courses in total Zuranolone 50 mg was generally well-tolerated with an overall adverse
View HTML
Toggle Summary Sage Therapeutics to Host Sage FutureCast Webcast
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 29, 2021-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that it will host Sage
View HTML
Toggle Summary Sage Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 24, 2021-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will
View HTML
Toggle Summary Sage Therapeutics to Present at the Stifel 2021 Virtual Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 11, 2021-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will
View HTML
Toggle Summary Sage Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
NDA submission for zuranolone for the treatment of MDD expected to be filed in the second half of 2022, with rolling submission planned to begin in early 2022 CORAL Study primary endpoint updated, in line with goal of study to demonstrate rapid reduction in depressive symptoms and benefits
View HTML
Toggle Summary Sage Therapeutics to Report Third Quarter 2021 Financial Results on Tuesday, November 2, 2021
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 20, 2021-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast
View HTML